We could not find any results for:
Make sure your spelling is correct or try broadening your search.
OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO Un abstract clinique sur les...
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO A clinical abstract on the induction results from the CoTikiS...
OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé OSE Immunotherapeutics annonce des avancées cliniques...
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites...
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary...
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant...
OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced...
OSE Immunotherapeutics Strengthens Leadership and Executive Committee OSE Immunotherapeutics Strengthens Leadership and Executive Committee NANTES, France, December 2, 2024 – 6:00pm CET - OSE...
OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif Nantes, France, le 2 décembre 2024...
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 3.21678321678 | 7.15 | 7.43 | 6.8 | 104981 | 7.04754644 | DE |
4 | -1.57 | -17.5418994413 | 8.95 | 9 | 6.8 | 144907 | 7.48640915 | DE |
12 | -1.56 | -17.4496644295 | 8.94 | 11.58 | 6.8 | 193487 | 9.1595356 | DE |
26 | 1.28 | 20.9836065574 | 6.1 | 11.58 | 5.37 | 186494 | 8.20526949 | DE |
52 | 3.28 | 80 | 4.1 | 11.58 | 3.115 | 170972 | 7.1509087 | DE |
156 | -3.02 | -29.0384615385 | 10.4 | 11.58 | 2.705 | 107271 | 6.34323124 | DE |
260 | 3.74 | 102.747252747 | 3.64 | 15.8 | 2.705 | 101565 | 7.4227915 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions